Impact (REF3a/b)

Impact template (REF3a)

Download template (263K)

All impact case studies

Download all case studies (9.9MB)

Individual case studies

A safer and shorter treatment for thyroid cancer (271K)

Advances in gene therapy lead to successful treatment of haemophilia (248K)

Alternatives to medication improve quality of life for children with epilepsy (255K)

Amyloidosis and acute phase proteins: development of new drugs and a new approach to academia-industry collaboration (121K)

Amyloidosis and acute phase proteins: world leading clinical service (202K)

B cell depletion: an effective therapy in rheumatoid arthritis (236K)

Biological characterisation and impact of HIV drug resistance (230K)

Buccal midazolam: a novel treatment for generalised convulsive seizures (231K)

Cell membrane biology in haemolytic anaemias: advances in diagnosis and treatment (257K)

Clinical and genetic characterisation of inherited forms of heart muscle disease and the impact on service provision and patient care (243K)

CT colonography for diagnosis of colorectal cancer in older symptomatic patients (225K)

Delivery of new methods for safer prenatal diagnosis: non-invasive testing using cell free fetal DNA in maternal blood (311K)

Development and validation of a biomarker for cytomegalovirus disease after transplant improves identification of patients at risk, speed of diagnosis and treatment (292K)

Development of new treatments for uveitis (229K)

Elucidating the early determinants of chronic lung disease: development of tools to enhance measurement and interpretation of lung function (242K)

Elucidating the genetics of deafness leads to better diagnosis and clinical services (352K)

Establishment of tacrolimus as the first choice calcineurin inhibitor for the immunosuppression regimen in liver transplant recipients (214K)

Evaluating and introducing pneumococcal conjugate vaccines (PCV) into the UK infant immunisation programme (210K)

Fundus autofluorescence imaging transforms understanding of retinal disease (373K)

Gene therapy for immunodeficiency diseases (238K)

Hereditary autoinflammatory disease programme: from endogenous pyrogen to the NHS cryopryin associated periodic syndrome (CAPS) Treatment Service at UCL, Royal Free Hospital. (277K)

Improved management of Acanthamoeba keratitis (234K)

Improved management of empyema in children (250K)

Improved surgical outcomes achieved through perioperative circulatory optimisation guided by oesophageal Doppler (235K)

Improving treatments for non-Hodgkin lymphomas (235K)

Improving vision of patients with angle-closure glaucoma (217K)

Inborn Errors of Metabolism: Diagnosis and Treatment (318K)

Inherited retinal disease: genetic testing and a new era of therapy (313K)

Introduction of aromatase inhibitors for the treatment of breast cancer (275K)

Introduction of percutaneous pulmonary valve implantation into clinical practice (346K)

Lung cancer research at UCL/UCLH sets standards of care (134K)

Management of systemic sclerosis – better follow up, risk stratification and use of immunosuppression (232K)

Moderate hypothermia as a therapy for neonatal encephalopathy improves survival and reduces disability (234K)

Molecular genetic characterisation of the causes of familial hypercholesterolaemia has led to improved diagnosis, prevention and treatment. (224K)

New treatment and treatment monitoring for iron overload in thalassaemia patients (250K)

Prevention and treatment of childhood obesity (356K)

Self-management intervention for men with lower urinary tract symptoms: development, phased evaluation and global adoption (233K)

Standard of care established for advanced biliary tract cancer (216K)

Stratification of treatment for adult patients with acute leukaemia (235K)

Targeted intraoperative radiotherapy at the time of lumpectomy for patients with early breast cancer as an alternative to conventional 3-6 weeks of postoperative radiotherapy (288K)

Targeting endothelin in systemic sclerosis – improved survival in pulmonary arterial hypertension (PAH) in systemic sclerosis and licensing of the first drug specifically for digital ulcers in systemic sclerosis (236K)

The development of pyrrolobenzodiazepine dimers as cancer therapeutics (312K)

The Moorfields Regression Analysis improves the management of glaucoma (251K)

The Moorfields Safer surgery System: new techniques revolutionise glaucoma surgery. (313K)

Tocilizumab – a new treatment for Rheumatoid Arthritis in adults and Juvenile Idiopathic Arthritis in children (237K)

Treatment of patients with Hodgkin lymphoma not responding to conventional dose therapy (223K)